The Question
Will drugs like Ozempic and Wegovy become the default treatment for obesity by 2035 — prescribed routinely, covered by insurance, reaching at least 1 in 10 eligible adults in high-income countries? That is the specific prediction we are making, at 84% confidence. The medical argument is settled. These drugs work. The question has always been whether governments, insurers and health systems would pay for them at the scale the data demands — and in the past year, that question has started to get an answer.
The drugs in question are called GLP-1 receptor agonists — they work by mimicking a hormone your gut naturally releases after eating, which tells your brain you're full and slows digestion. In major trials, semaglutide (sold as Ozempic for diabetes and Wegovy for obesity) and tirzepatide (Mounjaro, Zepbound) produced average weight loss of roughly 15–21% of body weight — results previously achievable mainly through surgery. And beyond the weight loss, the 2023 SELECT trial showed that semaglutide reduced heart attacks, strokes and cardiovascular deaths by 20% in people with obesity and existing heart disease. These drugs don't just slim you down. They protect your heart.
What the Evidence Shows
The SELECT trial changed the conversation. Before it, Ozempic was a weight-loss drug. After it, it became a cardiovascular drug — one that happens to cause weight loss. That reframing matters enormously for whether insurers will pay. A drug that cuts major heart events by 20% in high-risk patients is not a lifestyle luxury. It's a potential cost-saver. Research is also accumulating on benefits for fatty liver disease, sleep apnoea and kidney disease, and on reduced cravings for alcohol — though that last line of work is early.
Then came the access breakthroughs. In November 2025, the Trump administration struck deals with Novo Nordisk and Eli Lilly: Medicare would pay $245 a month for their obesity drugs, and cash prices on the government's TrumpRx site would start at $350 or less and fall toward $245. Since July 1, 2026, eligible Medicare patients have been able to get GLP-1s for obesity for a $50 monthly copay through a temporary program that runs to the end of 2027. In December 2025, the FDA approved the first GLP-1 pill for weight loss, an oral form of Wegovy that launched in January at $149 a month for the starting dose. The same month, the World Health Organization issued its first guideline on GLP-1 medicines for obesity. And as semaglutide patents expire in 2026, generic versions have launched in India at a small fraction of branded prices.
"While medication alone won't solve this global health crisis, GLP-1 therapies can help millions overcome obesity and reduce its associated harms."
— Dr Tedros Adhanom Ghebreyesus, WHO Director-General, December 2025For three years the question was whether anyone could afford these drugs. In 2026, the price finally started to break.
Why This Is Happening
The price problem was severe. In the United States, Wegovy's list price was around $1,350 a month — far beyond what most patients or public insurers could pay at scale. That is why the 2025 pricing deals matter: they moved the Medicare price to a fraction of list, and competition from pills and, abroad, generics is pushing prices down further. But the US coverage is temporary. Federal law still bars Medicare from routinely covering weight-loss drugs, so long-term coverage after 2027 depends on Congress.
During shortages in 2023 and 2024, a grey market emerged. Compounding pharmacies — facilities that can legally make their own versions of drugs in short supply — sold semaglutide and tirzepatide at a fraction of the brand-name cost. Once the FDA declared the shortages over, it moved to wind that market down, triggering legal battles. The episode showed how much demand there is at a lower price.
The clinical concerns are real too. Up to about 40% of the weight lost on these drugs can be lean mass rather than fat, which raises concerns for older patients. Nausea and stomach problems are common and cause a meaningful minority to stop. And stop taking the drug, and most of the weight tends to come back. This may be a treatment many people need for life — which is exactly why price matters so much.
What Could Happen
Pills, generics in markets where patents have expired, and competition between drugmakers push prices down through the late 2020s. Congress or its successors make Medicare coverage permanent, and other wealthy nations expand reimbursement following the WHO guideline. By 2035, a doctor prescribes a GLP-1 drug the way they prescribe a statin for cholesterol — routinely, affordably, as a first response.
Cheap oral drugs and generics make GLP-1s affordable out of pocket by the early 2030s. The insurance battles that might have lasted a decade become irrelevant, and access expands faster than health systems planned for.
US coverage lapses when the temporary Medicare program ends, price cuts stall, and long-term data on muscle loss in older patients restricts prescribing. A two-tier system entrenches itself: GLP-1s for the well-off, waiting lists for everyone else.
What Can We Do
If you're a patient considering these drugs, the evidence is clear on one thing: they work best alongside exercise, particularly resistance training. The drugs suppress appetite broadly, so patients who don't actively eat enough protein risk losing muscle alongside fat. This is not a passive treatment. Ask your doctor about a structured programme, not just a prescription.
For healthcare systems, the priority is clear protocols: who qualifies, how they're monitored, and what support they get alongside the drug. England's NICE approved semaglutide for specialist weight-management services in 2023 with specific BMI and health criteria, and with nutritional and exercise support built in — and in 2025 the NHS began a phased rollout of tirzepatide through family doctors. That combination of access and support is the right model.
For policymakers in the US, the fastest path to lasting, equitable access is deciding what happens when the temporary Medicare program ends in 2027. Prices have come down; coverage has not yet been made permanent. The Ozempic era is a test of whether health systems can turn a genuine breakthrough into genuine population health — and whether the political will exists to fund it.
- Wilding J.P.H. et al. — "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (STEP 1) — NEJM, 2021 (PubMed)
- Lincoff A.M. et al. — "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes" (SELECT) — NEJM, 2023 (PubMed)
- Jastreboff A.M. et al. — "Tirzepatide Once Weekly for the Treatment of Obesity" (SURMOUNT-1) — NEJM, 2022 (PubMed)
- CNBC — Trump announces deals with Eli Lilly and Novo Nordisk on obesity drug prices, November 2025
- CNBC — Medicare obesity drug coverage starting July 1, June 2026
- CNN — FDA approves the Wegovy pill, December 2025
- Fierce Pharma — Wegovy pill launches at $149 a month for the starter dose, January 2026
- World Health Organization — Global guideline on GLP-1 medicines for obesity, December 2025
- ThePrint — Indian drugmakers launch generic semaglutide, 2026
- NHS England — Medicines for obesity (tirzepatide phased rollout)
- NICE — Technology appraisal TA875: Semaglutide for managing overweight and obesity, 2023